Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HyperaFRA:HM6A -1.70%90 Return-on-Tangible-Equity is 113.79% as of Mar. 2026, which is 204% above its 10-year median of 37.39. GuruFocus rates FRA:HM6A with a GF Score™ of 90/100 and a GF Value™ of €5.38. The stock has 4 warning signs investors should review. Among 901 Drug Manufacturers companies, Hypera ranks better than 94.12% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hypera's annualized net income for the quarter that ended in Mar. 2026 was €230 Mil. Hypera's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €202 Mil. Therefore, Hypera's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 113.79%.
The historical rank and industry rank for Hypera's Return-on-Tangible-Equity or its related term are showing as below:
FRA:HM6A'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 28.06 Med: 37.39 Max: 710.06
Current: 305.65
During the past 13 years, Hypera's highest Return-on-Tangible-Equity was 710.06%. The lowest was 28.06%. And the median was 37.39%.
FRA:HM6A's Return-on-Tangible-Equity is ranked better than 94.12% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs FRA:HM6A: 305.65
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hypera Return-on-Tangible-Equity Related Terms
Hypera Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Hypera's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HM6A vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hypera's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 113.79% mean?
Hypera (FRA:HM6A) has a Return-on-Tangible-Equity of 113.79% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hypera and its competitors. This is 204% above median its historical median of 37.39. Over the past decade, Hypera's Return-on-Tangible-Equity has ranged from 28.06 to 710.06. According to the industry distribution chart, Hypera ranks #53 out of 901 companies in the Drug Manufacturers industry, placing it in the top 5.9%.
Is Hypera's Return-on-Tangible-Equity too high?
Hypera's current Return-on-Tangible-Equity of 113.79% is 204% above median its 10-year median of 37.39. Over the past 10 years, this metric has ranged from a low of 28.06 to a high of 710.06. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Hypera's value of 113.79% is 1340.4% above this industry median. Based on the distribution chart, Hypera ranks #53 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hypera has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Hypera's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #53 out of 901 companies for Return-on-Tangible-Equity. This places Hypera in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Hypera's value of 113.79% is 1340.4% above this benchmark. Historically, Hypera's own Return-on-Tangible-Equity has ranged from 28.06 to 710.06 over the past decade. While the company's 10-year median is 37.39 vs. the industry median of 7.90, Hypera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current Return-on-Tangible-Equity of 113.79% is 1340.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hypera and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current Return-on-Tangible-Equity is 113.79%, which is 204% above median its own 10-year median of 37.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Hypera (FRA:HM6A) has a current Return-on-Tangible-Equity of 113.79%. The stock's GF Value™ is €5.38, compared to a current price of €3.46 — trading 35.7% below its estimated fair value. The current Return-on-Tangible-Equity is 113.79%, which is 204% above median its 10-year median of 37.39 and 1340.4% above the Drug Manufacturers industry median of 7.90. Hypera's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hypera (FRA:HM6A), the current Return-on-Tangible-Equity is 113.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (FRA:HM6A) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of €3.46 is trading 35.7% below its estimated GF Value™ of €5.38.
Key valuation signals for FRA:HM6A:
Return-on-Tangible-Equity: 113.79% (204% above median its 10-year median of 37.39)
GF Value™: €5.38 vs. price of €3.46 (35.7% below fair value)
Industry Position: 1340.4% above the Drug Manufacturers median (#53 of 901)
No single metric tells the full story. See the FRA:HM6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
90GF Score
Get the complete analysis for FRA:HM6A
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HM6A has been successfully added to your 
